Lexicon Pharmaceuticals, Inc.
LXRX
$1.62
$0.010.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 60.24% | 1,255.21% | 1,504.83% | 1,250.63% | 2,479.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 60.24% | 1,255.21% | 1,504.83% | 1,250.63% | 2,479.34% |
| Cost of Revenue | 4.46% | -167.00% | -162.73% | -145.93% | -137.79% |
| Gross Profit | 33.22% | 358.06% | 351.14% | 215.70% | 192.38% |
| SG&A Expenses | -73.92% | -57.17% | -31.07% | -2.24% | 27.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -56.53% | -36.42% | -11.82% | 11.11% | 32.41% |
| Operating Income | 75.05% | 68.63% | 40.05% | 4.41% | -15.09% |
| Income Before Tax | 74.88% | 68.31% | 40.32% | 8.41% | -13.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 74.88% | 68.31% | 40.32% | 8.41% | -13.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.88% | 68.31% | 40.32% | 8.41% | -13.15% |
| EBIT | 75.05% | 68.63% | 40.05% | 4.41% | -15.09% |
| EBITDA | 75.30% | 68.85% | 40.18% | 4.41% | -15.16% |
| EPS Basic | 78.39% | 74.80% | 57.15% | 37.70% | 19.54% |
| Normalized Basic EPS | 78.26% | 74.98% | 57.20% | 37.62% | 19.30% |
| EPS Diluted | 78.39% | 74.80% | 57.15% | 37.70% | 19.54% |
| Normalized Diluted EPS | 78.26% | 74.98% | 57.20% | 37.62% | 19.30% |
| Average Basic Shares Outstanding | 13.52% | 24.74% | 38.46% | 48.50% | 44.76% |
| Average Diluted Shares Outstanding | 13.54% | 24.76% | 38.48% | 48.50% | 44.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |